Advertisement

Topics

AstraZeneca’s Tagrisso improves progression-free survival in Phase III NSCLC trial

19:00 EDT 30 Jul 2017 | Net Resources International

AstraZeneca has reported positive results from the Phase III FLAURA trial of Tagrisso (osimertinib) to treat patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC).

Original Article: AstraZeneca’s Tagrisso improves progression-free survival in Phase III NSCLC trial

NEXT ARTICLE

More From BioPortfolio on "AstraZeneca’s Tagrisso improves progression-free survival in Phase III NSCLC trial"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...